Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ATLCAR.κ.28 for Relapsed/Refractory Kappa+ NHL and CLL/SLL
NCT04223765Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Nov 2020
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATLCAR.kappa.28 in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of participants with adverse events at 4 weeks. Started Nov 2020; status: recruiting.
02
Drugs
ATLCAR.kappa.28
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04223765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223765.